A phase II feasibility study of carboplatin and nab-paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease (YLOG0114).
Hiroyuki SakashitaKen UchiboriYasuto JinToshiharu TsutsuiTakayuki HondaRie SakakibaraTakahiro MitsumuraYoshihisa NukuiTsuyoshi ShiraiMasahiro MasuoKozo SuharaHaruhiko FurusawaTakaaki YamashitaTakehiko OhbaKazuhito SaitoJun TakagiwaYoshihiro MiyashitaNaohiko InaseYasunari MiyazakiPublished in: Thoracic cancer (2022)
The 4-week modified regimen of carboplatin and nab-paclitaxel showed tolerable toxicity with favorable efficacy in NSCLC patients with ILD. This regimen may be an effective treatment option for patients in real clinical settings.
Keyphrases
- advanced non small cell lung cancer
- interstitial lung disease
- systemic sclerosis
- epidermal growth factor receptor
- phase ii
- end stage renal disease
- clinical trial
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- newly diagnosed
- open label
- phase ii study
- phase iii
- ejection fraction
- chronic kidney disease
- small cell lung cancer
- peritoneal dialysis
- oxidative stress
- placebo controlled
- squamous cell carcinoma